A US Senate committee advanced legislation aimed at limiting the cost of insulin for people with private health insurance to $35 per month. The move matters because insulin is essential for many people with diabetes, while high out-of-pocket costs can lead patients to ration treatment or face financial hardship.

The bill would apply the monthly cap to privately insured patients, complementing a separate $35 insulin cap for Medicare beneficiaries. Its prospects depended on wider Senate support, particularly because broader healthcare pricing measures have faced partisan disagreement.